University. During the first year of the study, in the pre-vaccine period, when PCV7 was approved and 1 2 9 available in the private market, but not yet implemented in the NIP, we found that only 2.7% and 1 3 0 2.3% of the children in EJ and PA respectively received at least one dose of the vaccine, and 1 3 1 only 1.2% in EJ and 0.7% in PA received at least two doses. Within a year of implementing 1 3 2 PCV7 in EJ, the proportion of children <2 years old who received at least one vaccine dose 1 3 3 increased to 75%. In PA, PCV10 was not introduced until late 2011, the proportion of children <2 years who received at least one dose of any PCV (PCV7 or PCV10) in PA before PCV10 1 3 5 implementation did not exceed 13%. This proportion increased to 85.5% three years after 1 3 6 implementing PCV10 in the vaccination program compared to 92% of children in EJ (p=0.03) 1 3 7 (Table 1) . (p trend =0.0092) during the first three study years (before PCV10 introduction), but did not 1 4 7 decrease further, three years after PCV10 was introduced (Fig 1) . The overall S. pneumoniae 1 4 8 carriage among children during the whole study period was 28.9% in EJ and 31.8% in PA. In the pre-vaccine study year, the proportion of VT strains among all pneumococcal isolates was Since the VT10-added serotypes were very rarely carried, the impact on VT7 carriage was 1 5 6
identical to that on VT10; therefore, we report only the impact on VT10 and VT13. During the 1 5 7
first two years following PCV7 implementation in EJ, but not yet in PA, a significant decrease 1 5 8
in VT10 strains was observed in EJ (p=0.0007), while no change was observed in PA 1 5 9
(p=0.8914), as described previously [7] .
A further significant decrease in VT10 serotypes was observed three years after the introduction 1 6 1 of PCV13 in EJ, with prevalence of VT10 strains decreasing to 5.7% (n=5) in 2014 (p=0.0006).
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In PA, following introduction of PCV10 in 2011, the prevalence of VT10 serotypes significantly 1 6 3 decreased from 41.9% (n=67) in 2011 to 19.0% (n=35) by 2014 (p<0.0001) (Fig 1) .
Concurrently, carriage of non-VT13 serotypes, increased over the years after introducing 1 6 5 PCV7/13 in EJ and they gradually replaced VT13 serotypes. In PA, carriage of non-VT13 1 6 6 serotypes did not change before PCV10 introduction (p=0.2527), but 3 years later the prevalence 1 6 7 almost doubled, replacing VT13 serotypes (p<0.0001) (Fig 1) .
When we assessed the rate of decrease in VT13 strains following the introduction of each of the 1 6 9 three vaccine introductions, a similar 50% reduction was observed within 3 years of 1 7 0 implementation of either PCV7 or PCV10 and an additional reduction of 67% in VT13 strains 1 7 1 was observed after PCV13 introduction ( PCV7, but no further decline was observed following PCV13 introduction. However, at the 1 9 0 same time serotype 3 increased from 0 cases in 2009 to 3/88 (3.4%) in 2014, although this 1 9 1 increase was only nearly statistically significant (p=0.056) (Table 3 ). In PA, before PCV10 1 9 2 implementation, a relatively stable prevalence of VT10 and VT13-added serotypes was 1 9 3 observed. Within three years following PCV10 implementation, a significant decrease in VT10, which was attributed to large decrease in serotypes 6B, 23F and 19F, was observed (from 30.0% 1 9 5 from the carriage in 2009 to 9.2% in 2014). Interestingly, a decrease was also observed in the 1 9 6 prevalence of two of the VT13-added serotypes: 6A (from 10.6% (n=17) to 4.9% (n=9), 1 9 7 p=0.045) and 19A (from 3.8% (n=6) to 1.6% (n=3), though not statistically significant). The 1 9 8 prevalence of serotype 3 did not change in this period (~4%). Non-VT13 serotypes gradually replaced VT13 serotypes; therefore, overall carriage of S. the introduction of PCV13 in EJ (p<0.001). As for PA, the proportion of non-VT13 serotypes 2 0 7 increased from 39.4% in the pre-PCV period (2011) to 70.7% in 2014 (p<0.001). Table 3 2 0 8 presents the most common non-VT13 serotypes in both regions and their proportion among all majority of VT10 serotypes (73.9%, n=17). Parental strains that belonged to non-VT13 serotypes 2 1 8 constituted 67.5% (n=27) and 72.1% (n=62) in EJ and PA, respectively (Table 4 ). The small 2 1 9 sample size of parental strains did not allow us to assess PCV effect on parental carriage or strain 2 2 0 distribution. Sixty percent of the parents who were carriers, had a child who was also a 2 2 1 pneumococcal carrier, yet, only 42.7% of those parent-child co-carrier pairs had an identical 2 2 2 serotype on screening. In both regions, once PCV was implemented, none of the VT13 carrier 2 2 3 parents had a child who carried a VT13 strain. We have previously reported the effects of PCV7 by comparing two closely related populations 2 3 0 in which PCV7 was implemented in one but not yet in the other [7] . In this study, we conducted The main vaccine impact of PCV implementation was the significant decrease in VT serotypes.
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More so, we show that a reduction of ~ 5 0% in VT13 serotypes was observed within three years 2 3 9 of implementation of PCV, whether PCV7 or PCV10 were used. This reduction was similar, 2 4 0 despite slightly different vaccine coverage rates (with 85% vaccine coverage of <2y in PA vs. which was shown to emerge following PCV10 in some studies but decrease, in other studies, 2 5 0 could be attributed to differences in the study design, different outcomes assessed (carriage, IPD, 2 5 1 etc.), or different vaccine coverage. Alternatively, the differences could be due to differences in and longer follow-up is required to determine the long-term impact of PCV10 on serotype 19A. The last of the three additional serotypes not included in PCV10 is serotype 3. Serotype 3 is 2 7 2 unique in many aspects, heavily encapsulated with a mucoid phenotype, highly resistant to PCV13 implementation [39, 40] . We show a nearly significant increase in serotype 3 following 2 7 8 PCV13 implementation in EJ (p=0.056) and no change after PCV10 implementation in PA.
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Whether serotype 3 will eventually decrease in a longer follow-up is yet to be seen. The relatively stable prevalence of S. pneumoniae carriage despite the significant reduction in Our study has a few limitations, mainly due to its design as an observational study. First, impact of the vaccines and to assess the long-term differences between the vaccines, longer follow-up is needed.
In conclusion, the unique settings of this study allowed us compare the initial effects of PCV13 
